DS-8273a

BIOLOGICAL2 trials

Sponsors

Daiichi Sankyo, NYU Langone Health

Conditions

Advanced Solid TumorLymphomaMelanoma

Phase 1

Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas

CompletedNCT02076451

Daiichi SankyoAdvanced Solid Tumor, Lymphoma

Start: 2014-02-28End: 2015-12-31Updated: 2019-02-12

Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma

CompletedNCT02983006

NYU Langone HealthMelanoma

Start: 2016-10-31End: 2021-01-01Updated: 2021-10-18

Related Papers

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

Clinical Cancer Research2023-06-0240 citations

C reactive protein impairs adaptive immunity in immune cells of patients with melanoma

Journal for ImmunoTherapy of Cancer2020-04-0193 citations

The knowledge system underpinning healthcare is not fit for purpose and must change

BMJ2015-06-03122 citations